Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical Thyroidology / Original Paper

Free Access

Hypothyroid Patients Encoding Combined MCT10 and DIO2 Gene Polymorphisms May Prefer L-T3 + L-T4 Combination Treatment – Data Using a Blind, Randomized, Clinical Study

Carlé A.a · Faber J.c,d · Steffensen R.b · Laurberg P.a · Nygaard B.c,d

Author affiliations

aDepartment of Endocrinology, Aalborg University Hospital, Aalborg, Denmark
bDepartment of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark
cDepartment of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
dFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Corresponding Author

Allan Carlé, MD, PhD

Department of Endocrinology

Aalborg University Hospital

DK–9000 Aalborg (Denmark)

E-Mail carle@dadlnet.dk

Related Articles for ""

Eur Thyroid J 2017;6:143–151

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Objectives: In previous studies, around half of all hypothyroid patients preferred levo-thyroxine (L-T4) + levo-triiodothyronine (L-T3) combination therapy, 25% preferred T4, and 25% had no preference. The reason for this is yet to be explored. Methods: A total of 45 overtly autoimmune, hypothyroid patients – now euthyroid on ≥6 months’ L-T4 therapy – participated in a prospective, double-blind, cross-over study. The patients were randomized into 2 groups of either 3 continuous months’ L-T4 therapy followed by 3 months’ combination therapy or vice versa. In all periods, 50 μg L-T4 was blindly replaced by either (identical) 50 μg L-T4 or by 20 μg T3. L-T4 was hereafter adjusted to obtain normal serum TSH values. We investigated 3 single nucleotide polymorphisms (SNPs) on the type II iodothyronine deiodinase (DIO2) gene (rs225014 (Thr92Ala), rs225015, and rs12885300 (ORFa-Gly3Asp)) and 1 SNP on the cellular membrane transport-facilitating monocarboxylate transporter (MCT10) gene (rs17606253), and asked in which of the 2 treatment periods patients felt better (i.e., which treatment was preferred). Results: 27 out of 45 patients (60%) preferred the combination therapy. Two polymorphisms (rs225014 (DIO2, Thr92Ala) and rs17606253 (MCT10)) were combined yielding 3 groups: none vs. 1 of 2 vs. both SNPs present, and 42 vs. 63 vs. 100% of our patients in the 3 groups preferred the combined treatment (Jongheere-Terpstra trend test, p = 0.009). Conclusion: The present study indicates that the combination of polymorphisms in DIO2 (rs225014) and MCT10 (rs17606253) enhances hypothyroid patients’ preference for L-T4 + L-T3 replacement therapy. In the future, combination therapy may be restricted or may be even recommended to individuals harbouring certain polymorphisms.

© 2017 European Thyroid Association. Published by S. Karger AG, Basel


  1. Carlé A, Laurberg P, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, Jorgensen T: Epidemiology of subtypes of hypothyroidism in Denmark. Eur J Endocrinol 2006;154: 21–28.
  2. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM: Psychological well-being in patients on “adequate” doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf) 2002;57: 577–585.
  3. Ladenson PW: Psychological wellbeing in patients. Clin Endocrinol (Oxf) 2002;57: 575–576.
  4. Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JG, Wiersinga WM: Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 2005;153: 747–753.
  5. Walsh JP: Dissatisfaction with thyroxine therapy – could the patients be right? Curr Opin Pharmacol 2002;2: 717–722.
  6. Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP: 2012 ETA Guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 2012;1: 55–71.
  7. Walsh JP, Shiels L, Lim EM, Bhagat CI, Ward LC, Stuckey BG, Dhaliwal SS, Chew GT, Bhagat MC, Cussons AJ: Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab 2003;88: 4543–4550.
  8. Nygaard B, Jensen EW, Kvetny J, Jarlov A, Faber J: Effect of combination therapy with thyroxine (T4) and 3,5,3′-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol 2009;161: 895–902.
  9. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr: Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999;340: 424–429.
  10. Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, Galan JM, Barrios V, Sancho J: Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 2005;142: 412–424.
  11. Bunevicius R, Jakuboniene N, Jurkevicius R, Cernicat J, Lasas L, Prange AJ Jr: Thyroxine vs thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves’ disease. Endocrine 2002;18: 129–133.
  12. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L: Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2006;91: 2592–2599.
  13. Carr D, McLeod DT, Parry G, Thornes HM: Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf) 1988;28: 325–333.
  14. Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG, Endert E, van Weert HC, Wiersinga WM: Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 2005;90: 2666–2674.
  15. Celi FS, Zemskova M, Linderman JD, Smith S, Drinkard B, Sachdev V, Skarulis MC, Koz­losky M, Csako G, Costello R, Pucino F: Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab 2011;96: 3466–3474.
  16. Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MK: Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab 2013;98: 1982–1990.
  17. Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, Dayan CM: Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009;94: 1623–1629.
  18. Friesema EC, Jansen J, Jachtenberg JW, Visser WE, Kester MH, Visser TJ: Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Mol Endocrinol 2008;22: 1357–1369.
  19. van der Deure WM, Peeters RP, Visser TJ: Genetic variation in thyroid hormone transporters. Best Pract Res Clin Endocrinol Metab 2007;21: 339–350.
  20. Dayan CM, Panicker V: Novel insights into thyroid hormones from the study of common genetic variation. Nat Rev Endocrinol 2009;5: 211–218.
  21. Nishimura M, Naito S: Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2008;23: 22–44.
  22. Visser TJ: Cellular uptake of thyroid hormones; in: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A (eds): Endotext [Internet]. South Dartmouth, MDText.com, Inc., 2000– (last update: June 15, 2016).
  23. Steffensen R, Baech J, Nielsen KR: Allelic discrimination by TaqMan-PCR for genotyping of human neutrophil antigens. Methods Mol Biol 2015;1310: 205–212.
  24. Rodriguez S, Gaunt TR, Day IN: Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009;169: 505–514.
  25. Peeters RP, van den Beld AW, Attalki H, Toor H, de Rijke YB, Kuiper GG, Lamberts SW, Janssen JA, Uitterlinden AG, Visser TJ: A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Am J Physiol Endocrinol Metab 2005;289:E75–E81.
  26. Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG, Visser TJ: Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab 2003;88: 2880–2888.
  27. Appelhof BC, Peeters RP, Wiersinga WM, Visser TJ, Wekking EM, Huyser J, Schene AH, Tijssen JG, Hoogendijk WJ, Fliers E: Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy. J Clin Endocrinol Metab 2005;90: 6296–6299.
  28. de Jong FJ, Peeters RP, den Heijer T, van der Deure WM, Hofman A, Uitterlinden AG, Visser TJ, Breteler MM: The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J Clin Endocrinol Metab 2007;92: 636–640.
  29. Gumieniak O, Perlstein TS, Williams JS, Hopkins PN, Brown NJ, Raby BA, Williams GH: Ala92 type 2 deiodinase allele increases risk for the development of hypertension. Hypertension 2007;49: 461–466.
  30. Panicker V, Cluett C, Shields B, Murray A, Parnell KS, Perry JR, Weedon MN, Singleton A, Hernandez D, Evans J, Durant C, Ferrucci L, Melzer D, Saravanan P, Visser TJ, Ceresini G, Hattersley AT, Vaidya B, Dayan CM, Frayling TM: A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J Clin Endocrinol Metab 2008;93: 3075–3081.
  31. Mentuccia D, Thomas MJ, Coppotelli G, Reinhart LJ, Mitchell BD, Shuldiner AR, Celi FS: The Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the old order of Amish. Thyroid 2005;15: 1223–1227.
  32. Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D’Arcangelo P, Dallapiccola B, Filetti S, Trischitta V: Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab 2008;93: 910–913.
  33. Butler PW, Smith SM, Linderman JD, Brychta RJ, Alberobello AT, Dubaz OM, Luzon JA, Skarulis MC, Cochran CS, Wesley RA, Pucino F, Celi FS: The Thr92Ala 5′ type 2 deiodinase gene polymorphism is associated with a delayed triiodothyronine secretion in response to the thyrotropin-releasing hormone-stimulation test: a pharmacogenomic study. Thyroid 2010;20: 1407–1412.
  34. Fadeyev VV, Madiyarova M, Morgunova: Evaluation the association of polymorphismes in DIO1 and DIO2 genes with mental, biochemical parameters and quality of life in women with primary hypothyroidism (abstract OP77). 38th Annual Meeting of the European Thyroid Association. Santiago de Compostela, September 2014.
  35. Heemstra KA, Hoftijzer HC, van der Deure WM, Peeters RP, Fliers E, Appelhof BC, Wiersinga WM, Corssmit EP, Visser TJ, Smit JW: Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis. Clin Endocrinol (Oxf) 2009;71: 279–283.
  36. Roef G, Taes Y, Toye K, Goemaere S, Fiers T, Verstraete A, Kaufman JM: Heredity and lifestyle in the determination of between-subject variation in thyroid hormone levels in euthyroid men. Eur J Endocrinol 2013;169: 835–844.
  37. Wouters HJ, van Loon HC, van der Klauw MM, Elderson MF, Slagter SN, Muller KA, Kema IP, Links TP, Vliet-Ostaptchouk JV, Wolffenbuttel BH: No effect of the Thr92Ala polymorphism of deiodinase-2 on thyroid hormone parameters, health-related quality of life, and cognitive functioning in a large population-based cohort study. Thyroid 2017;27: 147–155.
  38. Yalakanti D, Dolia PB: Association of type II 5′ monodeiodinase Thr92Ala single nucleotide gene polymorphism and circulating thyroid hormones among type 2 diabetes mellitus patients. Indian J Clin Biochem 2016;31: 152–161.
  39. Peltsverger MY, Butler PW, Alberobello AT, Smith S, Guevara Y, Dubaz OM, Luzon JA, Linderman J, Celi FS: The –258A/G (SNP rs12885300) polymorphism of the human type 2 deiodinase gene is associated with a shift in the pattern of secretion of thyroid hormones following a TRH-induced acute rise in TSH. Eur J Endocrinol 2012;166: 839–845.
  40. Medici M, van der Deure WM, Verbiest M, Vermeulen SH, Hansen PS, Kiemeney LA, Hermus AR, Breteler MM, Hofman A, Hegedus L, Kyvik KO, den Heijer M, Uitterlinden AG, Visser TJ, Peeters RP: A large-scale association analysis of 68 thyroid hormone pathway genes with serum TSH and FT4 levels. Eur J Endocrinol 2011;164: 781–788.
  41. Roef GL, Rietzschel ER, De Meyer T, Bekaert S, De Buyzere ML, Van daele C, Toye K, Kaufman JM, Taes YE: Associations between single nucleotide polymorphisms in thyroid hormone transporter genes (MCT8, MCT10 and OATP1C1) and circulating thyroid hormones. Clin Chim Acta 2013;425: 227–232.
  42. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR: Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002;23: 38–89.
  43. Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Andersen S, Laurberg P: Hypothyroid symptoms fail to predict thyroid insufficiency in old people: a population-based case-control study. Am J Med 2016;129: 1082–1092.
  44. Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P: Hypothyroid symptoms and the likelihood of overt thyroid failure: a population-based case-control study. Eur J Endocrinol 2014;171: 593–602.
  45. Medici M, van der Deure WM, Verbiest M, Vermeulen SH, Hansen PS, Kiemeney LA, Hermus AR, Breteler MM, Hofman A, Hegedüs L, Kyvik KO, den Heijer M, Uitterlinden AG, Visser TJ, Peeters RP: A large-scale association analysis of 68 thyroid hormone pathway genes with serum TSH and FT4 levels. Eur J Endocrinol 2011;164: 781–788.
  46. Taylor PN, Porcu E, Chew S, et al: Whole-genome sequence-based analysis of thyroid function. Nat Commun 2015;6: 5681.
  47. Wirth EK, Schweizer U, Kohrle J: Transport of thyroid hormone in brain. Front Endocrinol (Lausanne) 2014;5: 98.
  48. Friesema EC, Visser TJ, Borgers AJ, Kalsbeek A, Swaab DF, Fliers E, Alkemade A: Thyroid hormone transporters and deiodinases in the developing human hypothalamus. Eur J Endocrinol 2012;167: 379–386.
  49. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N: Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96: 434–442.
  50. Rothman KJ, Greenland S: Modern Epidemiology, ed 2. Philadelphia, Lippincott-Raven Publishers, 1988.
  51. Hill AB: The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295–300.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Clinical Thyroidology / Original Paper

Received: December 05, 2016
Accepted: March 07, 2017
Published online: April 24, 2017
Issue release date: June 2017

Number of Print Pages: 9
Number of Figures: 2
Number of Tables: 2

ISSN: 2235-0640 (Print)
eISSN: 2235-0802 (Online)

For additional information: https://www.karger.com/ETJ

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.